|Articles|August 5, 2010

EORTC Module 2: Recruitment, Treatment and Follow up Stage

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe

Related Content

© Tada Images - © Tada Images - stock.adobe.com

HHS Launches Operation TrialBlazer to Restore US Leadership in Clinical Research

ByAndy Studna, Senior Editor

June 23rd 2026

The Tufts Center for the Study of Drug Development has reported that the average number of eligibility criteria per protocol increased by over 60% between 2001 and 2020, and that the number of distinct procedures per trial visit tripled over the same period. Credit: Stock.Adobe.com/wladimir1804

Two Decades of Rising Protocol Complexity: A Longitudinal Analysis of Clinical Trial Design Evolution, 2004–2025

ByArtem Andrianov, PhD

June 23rd 2026

ACT Brief: ICON-Microsoft AI Partnership, DCT Site Burden, and AI-Enabled Neuroimmune Discovery

ByAndy Studna, Senior Editor

June 23rd 2026

2026 DIA Global Annual Meeting: Where Mixed Models Create the Most Value—and What It Takes to Make Them Work

BySamantha Hadfield,Nick Scott,Andy Studna, Senior Editor

June 22nd 2026

2026 DIA Global Annual Meeting: What Sites Struggle With and What the Data Will Eventually Tell Us About DCT

ByJoan Chambers,Andy Studna, Senior Editor

June 22nd 2026

EORTC Module 2: Recruitment, Treatment and Follow up Stage

Related Content

HHS Launches Operation TrialBlazer to Restore US Leadership in Clinical Research

Two Decades of Rising Protocol Complexity: A Longitudinal Analysis of Clinical Trial Design Evolution, 2004–2025

ACT Brief: ICON-Microsoft AI Partnership, DCT Site Burden, and AI-Enabled Neuroimmune Discovery

2026 DIA Global Annual Meeting: Where Mixed Models Create the Most Value—and What It Takes to Make Them Work

2026 DIA Global Annual Meeting: What Sites Struggle With and What the Data Will Eventually Tell Us About DCT

Trending on Applied Clinical Trials Online

ICON Selects Microsoft as Preferred Technology Partner to Scale Agentic AI Platform Across Clinical Trial Lifecycle

ACT Brief: Mixed FSP Strategy, DIA Meeting Trends, and Patient Voice in Oncology

ACT Brief: Real-Time Evidence Generation, Protocol Digitization, and Decentralized Trial Flexibility

ACT Brief: ICON-Microsoft AI Partnership, DCT Site Burden, and AI-Enabled Neuroimmune Discovery

2026 DIA Global Annual Meeting: Where Mixed Models Create the Most Value—and What It Takes to Make Them Work